Navigation Links
Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Date:3/20/2011

ding on the outcome of a formal appeal that CTI submitted to the Food & Drug Administration's (the "FDA") Office of New Drugs in the FDA's Center for Drug Evaluation and Research in December 2010 regarding its 2010 decision about CTI's new drug application (the "NDA") for pixantrone. The NDA for pixantrone was based on the results of the PIX 301 trial, a randomized trial comparing pixantrone as monotherapy to a choice of standard single-agent chemotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL") patients. CTI expects a decision regarding its appeal in the second quarter of 2011.

PIX-R TRIAL Design

The PIX-R trial is designed to be a randomized, multicenter study comparing pixantrone plus rituximab to gemcitabine plus rituximab in patients with relapsed or refractory DLBCL or DLBCL transformed from follicular lymphoma who have received one to three prior lines of therapy, including CHOP-R or an equivalent regimen. The patients to be enrolled in the PIX-R trial cannot be eligible for high-dose (myeloablative) chemotherapy and stem cell transplant, but patients who relapse after such a procedure are eligible. The co-primary endpoints for the PIX-R trial are PFS and OS with secondary endpoints including overall response rate ("ORR") (ORR equals complete responses plus partial responses), complete response rate and safety.  CTI is targeting to enroll 350 patients over 18 months in the PIX-R trial.

About Pixantrone

Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II, but unlike anthracyclines, rather than intercalation with DNA, pixantrone alkylates DNA and forms stable DNA adducts with particular specificity for CpG rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymph
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Northwest Biotherapeutics Addresses Recent Market Activity
2. MBL Signs Non-Exclusive License With Envoy Therapeutics for Access to RIP-Chip Technology
3. FDA Provides Guidance for Design of Cell Therapeutics Pixantrone Pivotal Trial
4. Reportlinker Adds Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017
5. Cell Therapeutics, Inc. (CTI) to Present at Bio Europe Spring 2011
6. Talecris Biotherapeutics Announces Record Date for 2011 Annual Meeting of Shareholders
7. Summer Street Research Partners Closes Financing for ImmunoCellular Therapeutics, Ltd.
8. MDAs Augies Quest Expands Testing of Potential ALS Therapeutics With New $2 Million Grant to ALS TDI
9. Cell Therapeutics, Inc. (CTI) to Present at Life Science Innovation Northwest
10. Pearl Therapeutics Appoints Charles (Chuck) Bramlage President and Chief Executive Officer
11. Talecris Biotherapeutics Announces Fourth Quarter and Full Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2014)... UMBC’s Biotechnology Graduate Programs’ Virtual ... 2014, from 12:00 to 1:00 p.m. EDT. The session ... and practice-oriented instruction, designed for working professionals. Participants will ... their career in the biotechnology industry. , If interested ... About UMBC’s Biotechnology Graduate Programs, UMBC offers a variety ...
(Date:9/13/2014)... Boehringer Laboratories Inc., with a forty year history ... successful broadcast of a live surgery by St. Luke’s ... FAMBS, and Maher El Chaar, MD, FACS, FAMBS, using ... This sleeve gastrectomy surgery was performed and broadcast live ... surgeons from around the world during the 5th International ...
(Date:9/12/2014)... Advancing the front lines of ... and biological threats is the mission of an ... (WPI) and the Georgian National Academy of Sciences, ... and Security Programme of the North Atlantic Treaty ... Workshop series, the event is titled “Nanotechnology to ...
(Date:9/12/2014)... On Thursday, September 11, 2014, the ... Industrial Average finished the day 0.12% lower at 17,049.00, and ... were broad based as seven out of ten sectors ended ... Index ended the day at 741.83, down 0.33%, while the ... has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: ...
Breaking Biology Technology:UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2Boehringer Laboratories, Inc. Announces Live Surgery Using Innovative System to Calibrate Sleeve Gastrectomy 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5
... WILL BE FOR USE IN POINT-OF-CARE BONE MARROW PROCESSING, ... KOOL ), a leading supplier of innovative products ... said it has,received authorization from the FDA to begin ... laboratory setting or intraoperatively,for preparation of a cell concentrate ...
... water through point-of-use ... ultrafiltration, NEW ... device company, announced today that it will be exhibiting its,Dual Stage ... Technical Exhibition in National Harbor,Maryland, July 20th-23rd, 2008. Building on the ...
... July 14 Phlo Corporation,(Pink Sheets: PHCP) (the ... California of its vitality beverage, AQISS(TM),will be significantly ... of,the largest specialty beverage distributors in the San ... reached an agreement in principal with Morris,Distributing providing ...
Cached Biology Technology:ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM)) 2ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM)) 3ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM)) 4Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 2Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 3Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 4Phlo Affiliate Announces Significant Distribution Expansion In California 2
(Date:9/15/2014)... in the Department of Science and Technology in Society ... at Virginia Tech, has won a 2014 National Science ... prospects and problems of creating a global nuclear emergency ... I Nuclear Power Plant in March 2011 was a ... emergencies, Schmid said. Three of the plant,s six nuclear ...
(Date:9/15/2014)... the oceans, there must be enough dissolved oxygen ... oxygen-starvation produces "dead zones" that decimate marine fisheries ... levels decline, energy is increasingly diverted away from ... impacts on the ecology and biogeochemistry of the ... minimum zones (OMZs) have expanded due to climate ...
(Date:9/15/2014)... and cognitive function may play roles in one,s musical ... pitch, timbre, tone durations, and formal structure in music. ... explain that extremes in musical aptitude (extreme capacity/no capacity) ... individuals having moderate aptitude. , "This is a typical ... genes, and it is influenced to varying degrees by ...
Breaking Biology News(10 mins):'Nuclear disasters don't respect national boundaries' 2Decoding virus-host interactions in the oxygen-starved ocean 2Decoding virus-host interactions in the oxygen-starved ocean 3Decoding virus-host interactions in the oxygen-starved ocean 4Decoding virus-host interactions in the oxygen-starved ocean 5
... Established in 2007 and based in Toronto, ArcticDx has ... kind and specifically designed to determine one,s inherited risk ... of acquired blindness in the developed world, affecting over ... investment to undertake studies in support of a planned ...
... One of the many advantages of maintaining a normal body ... healthy heart. Fat tissue is increasingly seen as more than ... organ that normally produces high levels of a cardioprotective hormone ... has long been a mystery, and now a team led ...
... the Morrison Natural History Museum have again discovered infant ... near the town of Morrison. Dating from the Late ... made before the Rocky Mountains rose, when Morrison was ... tracks represent infant sauropods, according to discoverer Matthew Mossbrucker, ...
Cached Biology News:OGI invests in personalized medicine for age-related macular degeneration 2Study finds fat hormone's long-sought link to heart protection 2Morrison Natural History Museum discovers baby sauropod tracks 2Morrison Natural History Museum discovers baby sauropod tracks 3
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
Direct ELISA Assay Diluent - EDTA, 10 L...
... gel electrophoresis into an automated, high-throughput operation ... pre-cast system is ideal for analyzing multiple ... more. Fully automated, robot-compatible, and ready to ... makes your high-throughput screening assignments as easy ...
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
Biology Products: